Revolutionizing
Alzheimer's Care
Cannabis-based drugs have the potential to improve the lives of millions with Alzheimer’s Disease
Alleviating the Debilitating Symptoms
of Alzheimer’s
Our drug candidate, IGC-AD1, has shown promising results in treating agitation for Alzheimer’s patients with dementia.
What We Do is Important
With no known cure, our formulations have the potential to change lives
Americans with
Alzheimer’s
Disease in 2022
Americans with
Alzheimer’s Disease
by 2060
5th Leading
Cause of death among
Americans age 65+
expected cost of Alzheimer’s and dementia by 2050 if no treatment or cure is found
What We Do
is Unique
60-70% of Alzheimer’s patients suffer from debilitating symptoms, including agitation, anxiety, and depression.
There are no FDA-approved
drugs to treat the symptoms
of dementia
for Alzheimer’s patients.
In 2022, only 6.9% of drugs
in clinical trials
were designed to treat the symptoms of Alzheimer’s.
IGC-AD1 is the only
cannabis-based drug
in clinical trials.
IGC-AD1 pre-clinical
studies showed
promise to treat agitation
and modify the progression of Alzheimer’s.
IGC-AD1 is the first drug that contains natural THC
to be tested on Alzheimer’s
patients in human trials.
IGC-AD1 contains ultra-low
doses of THC which minimizes safety risks and side effects.
Major Milestones
2013
Development of cannabis-based formulations for neurological disorders such as Alzheimer’s Disease, Epilepsy, and Tourette Syndrome began
2017
which we acquired from the University of South Florida to begin working on a liquid form of the drug.
2021
We completed a Phase 1
clinical study on our patented formulation (IGC-AD1)
to evaluate its safety and tolerability in participants with mild to severe Alzheimer’s Disease.
2022
We acquired a small NMI-derived molecule from Jawarlal Nehru Center for Advanced Studies (JNCSR), which was efficacious against phosphorylated tau in pre-clinical studies.
We launched a Phase 2 double-blind, multi-site, randomized trial
to evaluate the efficacy of IGC-AD1 on agitation due to dementia from Alzheimer’s.
